NEW ORLEANS — Nearly three-quarters of patients who received talquetamab for relapsed or refractory multiple myeloma had an objective response to therapy, results of the phase 1/phase 2 MonumenTAL-1 trial showed.
Data from the study — presented at ASH Annual Meeting and Exposition and published simultaneously in The New England Journal of Medicine — served as the basis for a biologics license application the agent’s manufacturer, Janssen, submitted to the FDA on Friday for treatment of patients with relapsed or refractory multiple myeloma.
“This is an exciting new
